PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 158 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $4,011,000 | -31.1% | 650,000 | -48.2% | 0.63% | -43.3% |
| Q1 2019 | $5,823,000 | +35.0% | 1,255,000 | +22.2% | 1.12% | +3.0% |
| Q4 2018 | $4,314,000 | -73.0% | 1,027,100 | -59.6% | 1.08% | -49.6% |
| Q3 2018 | $15,957,000 | -6.8% | 2,545,000 | +19.5% | 2.15% | -16.5% |
| Q2 2018 | $17,125,000 | +7.8% | 2,130,000 | 0.0% | 2.58% | +8.2% |
| Q1 2018 | $15,890,000 | +45.9% | 2,130,000 | +16.4% | 2.38% | +80.0% |
| Q4 2017 | $10,889,000 | -22.5% | 1,830,000 | -4.2% | 1.32% | -29.3% |
| Q3 2017 | $14,058,000 | +103.2% | 1,910,000 | +87.3% | 1.87% | +224.7% |
| Q2 2017 | $6,920,000 | +93.7% | 1,020,000 | +169.5% | 0.58% | +3.8% |
| Q1 2017 | $3,573,000 | +53.2% | 378,500 | +40.2% | 0.56% | +43.8% |
| Q4 2016 | $2,333,000 | -19.9% | 270,000 | -41.3% | 0.39% | -16.3% |
| Q3 2016 | $2,912,000 | +72.5% | 460,000 | +15.0% | 0.46% | +57.3% |
| Q2 2016 | $1,688,000 | – | 400,000 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|